Evotec stock holds at $1.91 as analysts stick to a hold view
Published on 08/30/2026 at 16:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE (ISIN DE0005664809) stock is trading at $1.91 as of August 28, 2026, underscoring how far the shares have retreated from their 2026 starting level and the potential upside implied by current analyst targets. The latest market data compiled on August 29, 2026 shows the shares closing at this level on Nasdaq under the ticker EVO, with a daily move of -3.05 percent that reflects ongoing volatility in biotech trading.
The same overview of recent trading shows that Evotec shares have moved within a daily range of $1.91 to $1.95 on August 28, 2026, marking a very tight intraday band compared with the broader 50-day trading span of $1.89 to $2.92. Over the past 52 weeks the stock has fluctuated between $1.87 and $4.27, a spread that highlights how sentiment has swung between optimism and concern for the company’s drug discovery pipeline and partnered development projects. With a reported market capitalization of $679.62 million as of August 28, 2026, Evotec remains a mid-cap biotech player, and that size influences how quickly new data or partnership announcements can change the stock’s trajectory.
Looking at year-to-date performance provides a quantified sense of how challenging 2026 has been for shareholders. According to the same market snapshot, Evotec’s stock was trading at $3.08 at the beginning of 2026 and has since declined to $1.91, which represents a drop of 38.0 percent over that span. That comparison between the $3.08 level at the start of the year and the current $1.91 price shows that the shares have lost more than one-third of their value during 2026, even as the company continues to pursue its strategy of partnering with pharmaceutical groups on early-stage discovery programs.
Analyst consensus and upside potential
Despite the tough share performance in 2026, the latest consensus data points to a moderate upside view on Evotec stock. The compiled analyst forecast assigns the shares a consensus rating of hold, with an average rating score of 2.20 on a scale that runs from zero to four. Within this framework there are no strong buy recommendations, two buy ratings, two hold ratings, and one sell recommendation, suggesting that professional coverage is fairly balanced and reflects both the promise and the risks tied to Evotec’s portfolio of partnered programs.
Price-target figures make the risk-reward profile more concrete. The current consensus price target for Evotec is reported at $3.00, based on the five analysts covering the stock in the referenced dataset. With the shares closing at $1.91 on August 28, 2026, this $3.00 target implies a potential upside of 57.1 percent from the present level if Evotec executes on its pipeline and partnership strategy. That quantitative gap between the $1.91 market price and the $3.00 target is one of the key numbers biotech investors watch when assessing whether the current valuation already factors in upcoming milestones or leaves room for positive surprises.
The distribution of individual price targets within that consensus range adds important nuance. The highest price target currently stands at $4.00, while the lowest sits at $2.00, framing a corridor of expectations that stretches from a modest recovery to a more robust rerating. When compared with the present $1.91 share price, the $2.00 low target signals that some analysts see only limited upside from here, whereas the $4.00 high target would require more than a doubling of the stock if achieved. This spread, anchored by a $3.00 mid-point, illustrates that opinions differ significantly and that Evotec’s subsequent clinical and partnership news will be critical for determining which scenario plays out.
Valuation, volatility, and trading context
Evotec’s current valuation metrics reflect its profile as a development-stage biotech with a diversified set of collaborations instead of a fully mature commercial portfolio. The share quote data shows that the company presently carries no meaningful trailing price-to-earnings ratio, underlining that earnings are not the main driver of the valuation narrative. Instead, investors focus on measures such as market capitalization, pipeline breadth, and the quality of revenue streams from partnerships, milestone payments, and potential future royalties.
Intraday and historical trading ranges reinforce the picture of a stock that can be reactive to news flows. On August 28, 2026 the daily range between $1.91 and $1.95 was narrow, but the 52-week range extending from $1.87 to $4.27 demonstrates that the shares have more than doubled from their low at times before giving up gains. Over the longer horizon of 2026, the movement from $3.08 at the start of the year to $1.91 at the latest close translates not only into the 38.0 percent decline but also into an indication that much of the optimism baked into the early-2026 price has been tested by subsequent developments.
Daily trading volume figures also characterize the liquidity available to investors entering or exiting positions. The same snapshot reports volume of 28,221 shares on August 28, 2026 compared with an average volume of 61,901 shares over a longer reference period, meaning that the latest session saw activity at a level below the usual. For investors, that lower-than-average turnover can imply both a quieter order book and potentially sharper price moves when larger orders hit the market, because fewer shares changing hands can amplify the impact of incremental demand or supply on the price.
Business model and partnered drug discovery
Evotec SE operates as a global biotechnology company headquartered in Hamburg, Germany, and its core business lies in providing drug discovery and development services through collaborations with pharmaceutical and biotech partners. The company has built platforms across target discovery, hit identification, lead optimization, and early development, allowing partners to outsource substantial parts of their R&D workflows while sharing in downstream economics if candidate drugs ultimately reach the market. That partnership-heavy model is central to understanding why investors focus so closely on alliance announcements and milestone payments when valuing the stock.
A representative example of Evotec’s approach is its work on small-molecule therapeutics within multi-year discovery alliances. In these collaborations Evotec contributes proprietary screening technologies, medicinal chemistry expertise, and integrated biology platforms to identify and refine molecules that address specified disease targets. Partners typically fund the research phases and compensate Evotec through research payments, with additional upside potential through development milestones and potential royalties if compounds advance through clinical trials and gain regulatory approval. For shareholders, these arrangements create a pipeline whose economic value depends on both the probability of technical success and the scale of commercial opportunities in the indications being pursued.
Evotec drug discovery platform
Beyond individual alliances, Evotec emphasizes its discovery and development platform as a key product-like offering to the pharmaceutical industry. This platform bundles high-throughput screening, structure-based drug design, and translational biology capabilities into an integrated service suite that can be deployed across multiple therapeutic areas. Pharmaceutical companies tap into this platform when they seek to accelerate early-stage projects or diversify their pipelines without building all capabilities in-house, making Evotec an important partner in the broader innovation ecosystem.
For investors, understanding this platform is important because it underpins both current revenues from research services and the longer-term optionality tied to milestones and royalties. A broad platform increases the number of shots on goal in terms of potential commercial drugs, but it also means that Evotec’s financial results can be influenced by the timing of milestone receipts and the progress of many separate programs. This dynamic contributes to the volatility observed in Evotec stock, as market participants react to news from individual collaborations that may change the perceived value of segments of the platform pipeline.
Evotec shares and current market level
Evotec shares continue to trade on Nasdaq under the ticker EVO, with the latest verified close of $1.91 recorded as of August 28, 2026 in U.S. dollars. That price sits close to the 52-week low of $1.87 yet significantly below the 52-week high of $4.27, situating the stock in the lower part of its recent trading band. For biotech-focused investors, this combination of a depressed price relative to the year’s peak and a consensus analyst target of $3.00 frames Evotec as a name where expectations have been reset but where the market still sees some potential for recovery if forthcoming data and partnership developments prove favorable.
Read more
Evotec stock overview and analyst data
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVO
Exchange: Nasdaq
Price (as of August 28, 2026, 4:00 p.m. ET): $1.91 USD
Market cap: $679.62 million (as of August 28, 2026)
Sector / Industry: Health care / Biotechnology
Index membership: None of the major U.S. large-cap indices
